Monday, November 9, 2020
- 9:00AM-11:00AM
-
Abstract Number: 1826
Maintenance of Efficacy and Safety and Reduction of BILAG Flares with Ustekinumab, an Interleukin-12/23 Inhibitor, in Patients with Active Systemic Lupus Erythematosus: 2-Year Results of a Phase 2, Randomized Placebo-Controlled, Crossover Study
SLE – Treatment Poster II- 9:00AM-11:00AM
-
Abstract Number: 1869
“Rheum to Diagnosis”: Uncovering Impediments to Accurate Diagnosis of Non-radiographic Axial Spondylarthritis (nr-axSpA)
Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III: Axial SpA- 9:00AM-11:00AM
-
Abstract Number: 1555
18F-NaF PET/CT Identifies Active Calcium Uptake in Calcinosis Due to Dermatomyositis and Scleroderma
Imaging of Rheumatic Diseases Poster- 9:00AM-11:00AM
-
Abstract Number: 1636
8 Years Follow-Up of a Novel Autoinflammatory Disease: CD59 Malfunction Causes Hemolytic Anemia, Recurrent Guillain-Barre Syndrome, and Strokes in Pediatric Populations and Respond Well to Eculizumab and Pozelimab
Miscellaneous Rheumatic & Inflammatory Diseases Poster III: Therapies- 9:00AM-11:00AM
-
Abstract Number: 1813
A Comprehensive Method to Study Environmental Chemicals in Serum in Patients with SLE
SLE – Diagnosis, Manifestations, & Outcomes Poster III: Bench to Bedside- 9:00AM-11:00AM
-
Abstract Number: 1650
A Double-Blind Randomized Trial to Evaluate the Efficacy of Corticosteroid Injections for Osteoarthritis of the Knee Using Mobile Devices
Osteoarthritis – Clinical Poster II- 9:00AM-11:00AM
-
Abstract Number: 1724
A Feasible and Efficient Approach to Implementing Rheumatoid Arthritis Disease Activity Measure in a Busy Rheumatology Clinic: A Quality Improvement Project
RA – Diagnosis, Manifestations, & Outcomes Poster IV: Lifespan of a Disease- 9:00AM-11:00AM
-
Abstract Number: 1797
A Multianalyte Assay Panel (MAP) with Algorithm Containing Cell-Bound Complement Activation Products (CB-CAPs) Is Superior to Anti-dsDNA and Low Serum Complement Levels in Predicting Transition of Probable Lupus to ACR Classified Lupus Within 2 Years
SLE – Diagnosis, Manifestations, & Outcomes Poster III: Bench to Bedside- 9:00AM-11:00AM
-
Abstract Number: 1840
A Novel Biomarker Identifies Systemic Lupus Erythematous (SLE) Patients Who Benefit from Obexelimab (XmAb®5871) Treatment
SLE – Treatment Poster II- 9:00AM-11:00AM
-
Abstract Number: 1745
A Novel Method for Predicting 1-Year Retention of Abatacept Using Machine Learning Techniques
RA – Diagnosis, Manifestations, & Outcomes Poster IV: Lifespan of a Disease- 9:00AM-11:00AM
-
Abstract Number: 1796
A Panel of Urinary Proteins Predicts Active Lupus Nephritis and Response to Rituximab Treatment
SLE – Diagnosis, Manifestations, & Outcomes Poster III: Bench to Bedside- 9:00AM-11:00AM
-
Abstract Number: 1588
A Quality Improvement Project to Improve Bone Densitometry Ordering in Adult Patients on Chronic Glucocorticoids
Measures & Measurement of Healthcare Quality Poster- 9:00AM-11:00AM
-
Abstract Number: 1591
A Quality Improvement Project to Increase Vitamin D Prescribing for Pediatric Patients on Glucocorticoids